




HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

HARMONY Networking Session at the 59th ASH Annual Meeting & Exposition

9th December 2017, Atlanta (GA), USA



Meet the HARMONY Executive Committee

Timeframe From 17:00 to 17:45

Venue Collaboration Room #32
Georgia World Congress Center
285 Andrew Young International Blvd NW,
Atlanta, GA 30313, US.

Participation is upon invitation only. If you are interested in attending, RSVP to Harmonyoffice@ibsal.es by 27th November.



1. Audience

- pharmaceutical companies that have shown interest in HARMONY before.
- pharmaceutical companies that have or may have an interest in the HARMONY IMI BD₄DO initiative.

2. Objectives

- Introduce and share HARMONY'S achievements so far.
- Identify and discuss potential involvement in HARMONY for new industry partners.

3. Programme

- Welcome and Introduction: "WHAT is HARMONY, WHY does it exist, WHO we are, UNIQUE aspects".
- One Year of SUCCESSFUL Funding.
- What's in HARMONY for COLLABORATION.
- Questions and Answers.

HARMONY Coordination Office

Institute of Biomedical Research of Salamanca (IBSAL)
Salamanca, Spain
Phone: +34 678 841 121
E-mail: harmonyoffice@ibsal.es

www.harmony-alliance.eu | [@harmonyNetEU](https://twitter.com/harmonyNetEU)

About the HARMONY Alliance: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology

The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 53 partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs).

The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

